Form 8.3 - [ AbbVie Inc.]
March 16 2020 - 10:43AM
Dow Jones News
TIDM0QCV TIDM0Y7T
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997,
TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING
1% OR MORE
1. KEY INFORMATION
Name of person dealing (Note 1) State Street Global Advisors &
Affiliates
--------------------------------------------- -------------------------------
Company dealt in AbbVie Inc.
--------------------------------------------- -------------------------------
Class of relevant security to which US$0.01 common stock
the dealings being disclosed relate (Note 2)
--------------------------------------------- -------------------------------
Date of dealing 13(th) March 2020
--------------------------------------------- -------------------------------
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of
relevant security dealt in (Note 3)
Long Short
------------------------------------- -------------------- -----------
Number (%) Number (%)
------------------------------------- ---------- -------- ------ ---
(1) Relevant securities 67,750,581 4.57013%
------------------------------------- ---------- -------- ------ ---
(2) Derivatives (other than options) N/A
------------------------------------- ---------- -------- ------ ---
(3) Options and agreements to
purchase/sell N/A
------------------------------------- ---------- -------- ------ ---
Total 67,750,581 4.57013%
------------------------------------- ---------- -------- ------ ---
(b) Interests and short positions in relevant securities of the company,
other than the class dealt in (Note 3)
Class of relevant security: Long Short
------------------------------------------- ----------- -----------
Number (%) Number (%)
------------------------------------------- ------ --- ------ ---
(1) Relevant securities N/A
------------------------------------------- ------ --- ------ ---
(2) Derivatives (other than options) N/A
------------------------------------------- ------ --- ------ ---
(3) Options and agreements to purchase/sell N/A
------------------------------------------- ------ --- ------ ---
Total N/A
------------------------------------------- ------ --- ------ ---
3. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale Number of relevant securities Price per unit (Note 5)
-------------- ----------------------------- -----------------------
Purchase 400 81.70
-------------- ----------------------------- -----------------------
Purchase 1,400 85.37
-------------- ----------------------------- -----------------------
Purchase 1,400 85.37
-------------- ----------------------------- -----------------------
Purchase 4,600 85.37
-------------- ----------------------------- -----------------------
Purchase 59 80.89
-------------- ----------------------------- -----------------------
Purchase 986 83.17
-------------- ----------------------------- -----------------------
Purchase 1,788 85.37
-------------- ----------------------------- -----------------------
Purchase 17,780 85.37
-------------- ----------------------------- -----------------------
Purchase 8,890 85.37
-------------- ----------------------------- -----------------------
Purchase 5,979 85.37
-------------- ----------------------------- -----------------------
Purchase 13,951 85.37
-------------- ----------------------------- -----------------------
Purchase 1,160 85.37
-------------- ----------------------------- -----------------------
Purchase 2,910 85.37
-------------- ----------------------------- -----------------------
Purchase 39 85.37
-------------- ----------------------------- -----------------------
Purchase 1,600 81.70
-------------- ----------------------------- -----------------------
Purchase 353 85.37
-------------- ----------------------------- -----------------------
Purchase 4,880 85.37
-------------- ----------------------------- -----------------------
Purchase 1,952 85.37
-------------- ----------------------------- -----------------------
Purchase 269 85.37
-------------- ----------------------------- -----------------------
Purchase 269 85.37
-------------- ----------------------------- -----------------------
Purchase 15 84.79
-------------- ----------------------------- -----------------------
Sale 400 84.71
-------------- ----------------------------- -----------------------
Sale 2,864 83.27
-------------- ----------------------------- -----------------------
Sale 198 85.37
-------------- ----------------------------- -----------------------
Sale 1,400 85.37
-------------- ----------------------------- -----------------------
Sale 1,300 84.44
-------------- ----------------------------- -----------------------
Sale 163 81.57
-------------- ----------------------------- -----------------------
Sale 262 85.37
-------------- ----------------------------- -----------------------
Sale 2,716 85.37
-------------- ----------------------------- -----------------------
Sale 909 85.37
-------------- ----------------------------- -----------------------
Sale 49,926 85.37
-------------- ----------------------------- -----------------------
Sale 735 85.37
-------------- ----------------------------- -----------------------
Sale 3,786 85.37
-------------- ----------------------------- -----------------------
Sale 299 85.37
-------------- ----------------------------- -----------------------
Sale 4,889 85.37
-------------- ----------------------------- -----------------------
Sale 4,304 85.37
-------------- ----------------------------- -----------------------
Sale 1,138 85.37
-------------- ----------------------------- -----------------------
Sale 1,400 85.37
-------------- ----------------------------- -----------------------
Sale 48,700 85.37
-------------- ----------------------------- -----------------------
(b) Derivatives transactions (other than options transactions)
Product name, Nature of transaction Number of relevant securities Price per unit
e.g. CFD (Note 6) (Note 7) (Note 5)
------------- --------------------- ----------------------------- --------------
N/A
------------- --------------------- ----------------------------- --------------
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name, Writing, selling, Number of Exercise Type, e.g. Expiry Option money
e.g. call option purchasing securities to which price American, date paid/received
varying etc. the option relates European etc. per unit (Note 5)
(Note 7)
----------------- ----------------- -------------------- -------- -------------- ------ ------------------
N/A
----------------- ----------------- -------------------- -------- -------------- ------ ------------------
(ii) Exercising
Product name, Number of securities Exercise price per
e.g. call option unit (Note 5)
----------------- -------------------- ------------------
N/A
----------------- -------------------- ------------------
(d) Other dealings (including transactions in respect of new securities)
(Note 4)
Nature of transaction Details Price per unit
(Note 8) (if applicable) (Note 5)
--------------------- ------- -------------------------
N/A
--------------------- ------- -------------------------
4. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or
derivatives
Full details of any agreement, arrangement or understanding
between the person disclosing and any other person
relating to the voting rights of any relevant securities
under any option referred to on this form or relating
to the voting rights or future acquisition or disposal
of any relevant securities to which any derivative
referred to on this form is referenced. If none, this
should be stated.
-----------------------------------------------------------
N/A
-----------------------------------------------------------
Is a Supplemental Form 8 attached? (Note 9) NO
------------------------------------------------------- -----------------
Date of disclosure 16(th) March 2020
------------------------------------------------------- -----------------
Contact name Lionel Colaco
------------------------------------------------------- -----------------
Telephone number 020 33956098
------------------------------------------------------- -----------------
If a connected EFM, name of offeree/offeror with which N/A
connected
------------------------------------------------------- -----------------
If a connected EFM, state nature of connection (Note N/A
10)
------------------------------------------------------- -----------------
(END) Dow Jones Newswires
March 16, 2020 10:28 ET (14:28 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Allergan (NYSE:AGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Allergan (NYSE:AGN)
Historical Stock Chart
From Sep 2023 to Sep 2024
